Immunotherapy Sector




The global drug market has reached 754 billion dollars of revenues in 2013 and it is expected to exceed $1000 billion by 2020. Although a recent new class of molecules compared with the chemical molecules, the biotherapeutic molecules already accounted for 200 billion dollars in 2013 representing 27% of the global drug market and it is expected to rise to almost $ 400 billion in 2020, representing 40% of drug sales.

The immunotherapy market alone represents 53% of the biotherapeutic molecules in 2013 and is expected to grow to 57% by 2020.  It is this segment in strong growth that MabDesign aims to support and contribute to its structuration.

The monoclonal antibodies (mAbs) is also a growing market representing by itself 75 billion dollars of revenues in 2013 representing nearly 2/3 of the immunotherapy market.  In 2015, 60 mAbs were approved worldwide. The mAbs market is estimated to reach $90 billion in 2017.

This strong growth of immunotherapies is linked to the extreme efficiency of these tools to treat conditions for which chemical molecules are sometimes a failure.  Immunotherapies bring therapeutic solutions for a large spectrum of indications including inflammatory, infectious and auto-immune diseases, rare diseases or cancers.



Immunotherapies are treatments that use the immune system to prevent or treat diseases by inducing, enhancing or suppressing an immune response.  Immunotherapies can be either active, by mobilizing or reinforcing the host intrinsic immune system to a disease (i.e. therapeutic vaccines, checkpoint agents) or passive (by using immune system components that are made outside of the body) and administered to patients to provide immunity against a disease (i.e. mAbs, ADCs). Their action can be either specific by directly aiming the target of the disease (i.e. vaccines, mAbs), or non-specific involving an intermediate target that will have an effector role (i.e. mAbs, cells, or proteins).


The Immunotherapy sector can be divided into four main areas:

A support tool is indispensable to the development of immunotherapies and that is relevant to all four areas: the companion biomarkers.



This is a unique website which will require a more modern browser to work!

Please upgrade today!